Search

Your search keyword '"Alfonso, Zaccaria"' showing total 90 results

Search Constraints

Start Over You searched for: Author "Alfonso, Zaccaria" Remove constraint Author: "Alfonso, Zaccaria" Topic medicine.disease Remove constraint Topic: medicine.disease
90 results on '"Alfonso, Zaccaria"'

Search Results

1. Bortezomib, thalidomide, and dexamethasone followed by double autologous haematopoietic stem-cell transplantation for newly diagnosed multiple myeloma (GIMEMA-MMY-3006): long-term follow-up analysis of a randomised phase 3, open-label study

2. All-trans retinoic acid and in vitro cytokine production by acute promyelocytic eukemia cells

Catalog

Books, media, physical & digital resources

3. Fludarabine treatment in resistant Waldenstrom's macroglobulinemia

4. Prediction of response to imatinib by prospective quantitation of BCR-ABL transcript in late chronic phase chronic myeloid leukemia patients

5. Differences among young adults, adults and elderly chronic myeloid leukemia patients

6. Randomized trial of 8-week versus 12-week VNCOP-B plusG-CSF regimens as front-line treatment in elderly aggressive non-Hodgkin’s lymphoma patients

7. Lenalidomide monotherapy in heavily pretreated patients with non-Hodgkin lymphoma: an Italian observational multicenter retrospective study in daily clinical practice

8. Lenalidomide plus R-CHOP21 in elderly patients with untreated diffuse large B-cell lymphoma: results of the REAL07 open-label, multicentre, phase 2 trial

9. A new method of 'in-cell reverse transcriptase-polymerase chain reaction' for the detection of BCR/ABL transcript in chronic myeloid leukemia patients

10. A 41-gene signature predicts complete response (CR) to Bortezomib-Thalidomide-Dexamethasone (VTD) as induction therapy prior to autologous stem-cell transplantation (ASCT) in multiple myeloma (MM)

11. Long-term efficacy and toxicity results of the FLUMIZ trial (fludarabine and mitoxantrone followed by yttrium-90 ibritumomab tiuxetan in untreated follicular lymphoma)

12. Increased expression of myeloid antigen markers in adult acute lymphoblastic leukaemia patients: diagnostic and prognostic implications

13. Long Term Efficacy of Percutaneous Vertebroplasty in Multiple Myeloma (MM) Patients: Experience of the 'Gruppo Ematologico Di Romagna' (GER)

14. A simple prognostic scoring system for newly diagnosed cytogenetically normal acute myeloid leukemia: retrospective analysis of 530 patients

15. t(8;14)(q11;q32) in acute lymphoid leukemia

16. Evaluation of Residual CD34+/Ph+ Stem Cells In Chronic Myeloid Leukemia Patients In Complete Cytogenetic Response during First Line Nilotinib Therapy

17. Health-Related Quality of Life In Patients with Chronic Myeloid Leukemia Undergoing First Line Treatment with Imatinib for at Least Three Years Compared with the General Population. A Multicenter Study Including 448 Patients

18. Chronic myeloid leukemia: a prospective comparison of interphase fluorescence in situ hybridization and chromosome banding analysis for the definition of complete cytogenetic response: a study of the GIMEMA CML WP

19. Hairy cell leukemias with unmutated IGHV genes define the minor subset refractory to single-agent cladribine and with more aggressive behavior

20. Confirmation and improvement of Sokal's prognostic classification of Ph+ chronic myeloid leukemia: The value of early evaluation of the course of the disease

21. Fludarabine and mitoxantrone followed by yttrium-90 ibritumomab tiuxetan in previously untreated patients with follicular non-Hodgkin lymphoma trial: a phase II non-randomised trial (FLUMIZ)

22. SUPERIOR COMPLETE RESPONSE RATE AND PROGRESSION-FREE SURVIVAL AFTER AUTOLOGOUS TRANSPLANTATION WITH UP-FRONT VELCADE-THALIDOMIDE- DEXAMETHASONE COMPARED WITH THALIDOMIDE-DEXAMETHASONE IN NEWLY DIAGNOSED MULTIPLE MYELOMA

23. High and Early Rates of Cytogenetic and Molecular Response with Nilotinib 800 Mg Daily as First Line Treatment of Ph-Positive Chronic Myeloid Leukemia in Chronic Phase: Results of a Phase 2 Trial of the GIMEMA CML Working Party

24. New type of Bcr/Abl junction in Philadelphia chromosome-positive chronic myelogenous leukemia

25. Fungal and bacterial infections in acute myeloid leukemia patients treated with induction regimens including fludarabine: a retrospective analysis of 224 cases

26. Persistence of chromosomal abnormalities additional to the Philadelphia chromosome after Philadelphia chromosome disappearance during imatinib therapy for chronic myeloid leukemia

27. A prospective randomized study of rituximab and dexamethasone vs dexamethasone alone in ITP

28. Tosedostat Plus Low Dose Cytarabine Induces a High Rate of Responses That Can be Predicted By Genetic Profiling in Elderly AML

29. CHOP-rituximab with pegylated liposomal doxorubicin for the treatment of elderly patients with diffuse large B-cell lymphoma

30. Hairy cell leukemias (HCL) with unmutated V-genes have a poorer response to single agent 2CdA than HCL with mutated V-genes

31. PEG Intron Treatment in 90 Patients with Essential Thrombocythemia (ET) Final Report of a Phase II Study

32. Multicentre phase III trial on fludarabine, cytarabine (Ara-C), and idarubicin versus idarubicin, Ara-C and etoposide for induction treatment of younger, newly diagnosed acute myeloid leukaemia patients

33. Efficacy and toxicity of FLAI vs ICE for induction treatment of newly diagnosed AML paztients, younger than 60 years

34. FLAG (fludarabine + cytosine arabinoside + G-CSF) induces complete remission in acute-phase chronic myeloid leukaemia: a case report

35. Induction of 'In Vitro' Apoptosis by Fludarabine in Freshly Isolated B-Chronic Lymphocytic Leukemia Cells

36. Cryptic translocation of PML/RARA on 17q. A rare event in acute promyelocytic leukemia

37. Low Toxicity Profile of the Combination of Bendamustine Plus Rituximab (BR) in Elderly FRAIL Patients with Newly Diagnosed DLBCL

38. Nongastrointestinal Low- Grade mucosa-associated lymphoid tissue lymphoma: analysis of 75 patients

39. Occurrence of the same chromosome abnormalities in Ph+and Ph?cells in chronic myeloid leukaemia. Evidence of a secondary origin of the Ph chromosome?

40. Final Results Of Phase II Study Of Lenalidomide Plus Rituximab-CHOP21 In Elderly Untreated Diffuse Large B-Cell Lymphoma Focusing On The Analysis Of Cell Of Origin: REAL07 Trial Of The Fondazione Italiana Linfomi

41. Abstract 2207: A 41-gene signature predicts complete response (CR) to Bortezomib-Thalidomide-Dexamethasone (VTD) as induction therapy prior to autologous stem-cell transplantation (ASCT) in multiple myeloma (MM)

42. Results of a Phase II Study of Lenalidomide in Combination with Rituximab for the Treatment of Indolent Non Follicular Non Hodgkin Lymphoma (NHL)

43. Lenalidomide Is Effective in Heavily Pretreated Non Hodgkin Lymphoma (NHL): Analysis of a Retrospective Data Collection

44. Interferon alfa-2a as compared with conventional chemotherapy for the treatment of chronic myeloid leukemia

45. Four-chromosomes complex translocations in acute promyelocytic leukemia: description of two cases

46. Drug Resistance and Bcr-Abl Kinase Domain Mutations In Philadelphia-Positive Acute Lymphoblastic Leukemia From the Imatinib to the 2nd-Generation Tyrosine Kinase Inhibitor Era: The Main Changes Are In the Type of Mutations, but Not In the Frequency of Mutation Involvement

47. Fludarabine and Mitoxantrone Followed by Yttrium-90 Ibritumumab Tiuxetan in Untreated Patients with Follicular Lymphoma. Long Term Efficacy and Toxicity Results of the FLUMIZ Trial

49. Analysis of Toxicity and Efficacy of Subcutaneous Cladribine at Reduced or Standard Doses (Five Versus Seven Consecutive Days) In Patients with Hairy Cell Leukemia (HCL) In the ICGHCL2004 Protocol by the Italian Cooperative Group on Hcl

50. Analysis of Parameters Predicting Treatment Efficacy and Outcome In Patients with Hairy Cell Leukemia (HCL) Receiving Subcutaneous Cladribine In the ICGHCL2004 Protocol (by the Italian Cooperative Group on HCL)